{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:19:16Z","timestamp":1776259156854,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,15]]},"DOI":"10.7759\/cureus.107083","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:25:07Z","timestamp":1776255907000},"source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Nephropathy: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Jaisingh","family":"Rajput","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajakta V","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nihar","family":"Jena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek Kumar","family":"Mariswamy Arun Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elan","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saketh","family":"Parsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic RZ","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017, 12:2032-45. 10.2215\/CJN.11491116","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis EJ","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345:851-60. 10.1056\/NEJMoa011303","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.691878","article-title":"Canagliflozin for prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Tian L","year":"2021","unstructured":"Tian L, Cai Y, Zheng H, et al.. Canagliflozin for prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021, 12:691878. 10.3389\/fphar.2021.691878","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0209","article-title":"Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics","volume":"46","author":"Kim NH","year":"2022","unstructured":"Kim NH, Kim NH. Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics. Diabetes Metab J. 2022, 46:543-51. 10.4093\/dmj.2022.0209","journal-title":"Diabetes Metab J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213749","article-title":"Sodium-glucose cotransporter-2 inhibitors - miracle drugs for the treatment of chronic kidney disease irrespective of diabetes status: lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials","volume":"23","author":"Gohda T","year":"2022","unstructured":"Gohda T, Murakoshi M. Sodium-glucose cotransporter-2 inhibitors - miracle drugs for the treatment of chronic kidney disease irrespective of diabetes status: lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials. Int J Mol Sci. 2022, 23:13749. 10.3390\/ijms232213749","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire DK","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al.. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021, 6:148-58. 10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins JP","year":"2024","unstructured":"Higgins JP, Morgan RL, Rooney AA, et al.. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024, 186:108602. 10.1016\/j.envint.2024.108602","journal-title":"Environ Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2188\/jea.15.235","article-title":"Systematic evaluation and comparison of statistical tests for publication bias","volume":"15","author":"Hayashino Y","year":"2005","unstructured":"Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005, 15:235-43. 10.2188\/jea.15.235","journal-title":"J Epidemiol"},{"key":"ref13","unstructured":"The Cochrane Collaboration. (2020). Accessed. October 5, 2025: https:\/\/training.cochrane.org\/online-learning\/core-software\/revman."},{"key":"ref14","unstructured":"RStudio. integrated development environment for R [software]. (2026). Accessed: October 15, 2025: https:\/\/posit.co\/download\/rstudio-desktop\/."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142243","article-title":"Pharmacological treatment of hyperglycemia in type 2 diabetes","volume":"131","author":"Taylor SI","year":"2021","unstructured":"Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021, 131:142243. 10.1172\/JCI142243","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108357","article-title":"Present and future directions in diabetic kidney disease","volume":"36","author":"Limonte CP","year":"2022","unstructured":"Limonte CP, Kretzler M, Pennathur S, Pop-Busui R, de Boer IH. Present and future directions in diabetic kidney disease. J Diabetes Complications. 2022, 36:108357. 10.1016\/j.jdiacomp.2022.108357","journal-title":"J Diabetes Complications"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76130","article-title":"The role of sodium-glucose co-transporter-2 inhibitors in treating lupus nephritis: a systematic review","volume":"16","author":"Nagy S","year":"2024","unstructured":"Nagy S, Kesselman MM. The role of sodium-glucose co-transporter-2 inhibitors in treating lupus nephritis: a systematic review. Cureus. 2024, 16:e76130. 10.7759\/cureus.76130","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow GM","year":"2021","unstructured":"Chertow GM, Vart P, Jongs N, et al.. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021, 32:2352-61. 10.1681\/ASN.2021020167","journal-title":"J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze AD","year":"2022","unstructured":"Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022, 21:47. 10.1186\/s12933-022-01476-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016, 375:323-34. 10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler DC","year":"2020","unstructured":"Wheeler DC, Stefansson BV, Batiushin M, et al.. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020, 35:1700-11. 10.1093\/ndt\/gfaa234","journal-title":"Nephrol Dial Transplant"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama T","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, et al.. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019, 21:1237-50. 10.1111\/dom.13648","journal-title":"Diabetes Obes Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.031623","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis","volume":"52","author":"Zhou Z","year":"2021","unstructured":"Zhou Z, Jardine MJ, Li Q, et al.. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 2021, 52:1545-56. 10.1161\/STROKEAHA.120.031623","journal-title":"Stroke"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine MJ","year":"2020","unstructured":"Jardine MJ, Zhou Z, Mahaffey KW, et al.. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020, 31:1128-39. 10.1681\/ASN.2019111168","journal-title":"J Am Soc Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020050723","article-title":"Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post-hoc analysis from the CREDENCE trial","volume":"31","author":"Oshima M","year":"2020","unstructured":"Oshima M, Neuen BL, Li J, et al.. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post-hoc analysis from the CREDENCE trial. J Am Soc Nephrol. 2020, 31:2925-36. 10.1681\/ASN.2020050723","journal-title":"J Am Soc Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.08.019","article-title":"A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope","volume":"106","author":"Miyamoto S","year":"2024","unstructured":"Miyamoto S, Heerspink HJ, de Zeeuw D, et al.. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney Int. 2024, 106:972-84. 10.1016\/j.kint.2024.08.019","journal-title":"Kidney Int"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (CKD stage 3A): the DERIVE study","volume":"20","author":"Fioretto P","year":"2018","unstructured":"Fioretto P, Del Prato S, Buse JB, et al.. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (CKD stage 3A): the DERIVE study. Diabetes Obes Metab. 2018, 20:2532-40. 10.1111\/dom.13413","journal-title":"Diabetes Obes Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13778","article-title":"Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter\u20092 inhibitor in patients with diabetic kidney disease: subanalysis of two phase\u2009III studies","volume":"13","author":"Shikata K","year":"2022","unstructured":"Shikata K, Ito S, Kashihara N, et al.. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter\u20092 inhibitor in patients with diabetic kidney disease: subanalysis of two phase\u2009III studies. J Diabetes Investig. 2022, 13:1190-202. 10.1111\/jdi.13778","journal-title":"J Diabetes Investig"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner C","year":"2018","unstructured":"Wanner C, Heerspink HJ, Zinman B, et al.. Empagliflozin and kidney function decline in patients with type 2 diabetes: slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol. 2018, 29:2755-69. 10.1681\/ASN.2018010103","journal-title":"J Am Soc Nephrol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01130121","article-title":"Ertugliflozin and slope of chronic eGFR: analyses from the VERTIS CV trial","volume":"16","author":"Cherney DZ","year":"2021","unstructured":"Cherney DZ, Cosentino F, Dagogo-Jack S, et al.. Ertugliflozin and slope of chronic eGFR: analyses from the VERTIS CV trial. Clin J Am Soc Nephrol. 2021, 16:1345-54. 10.2215\/CJN.01130121","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13624","article-title":"Renal, cardiovascular and safety outcomes of canagliflozin in patients with type\u20092 diabetes and nephropathy in East and South-East Asian countries: results from the canagliflozin and renal events in diabetes with established nephropathy clinical evaluation trial","volume":"13","author":"Wada T","year":"2022","unstructured":"Wada T, Mori-Anai K, Kawaguchi Y, et al.. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type\u20092 diabetes and nephropathy in East and South-East Asian countries: results from the canagliflozin and renal events in diabetes with established nephropathy clinical evaluation trial. J Diabetes Investig. 2022, 13:54-64. 10.1111\/jdi.13624","journal-title":"J Diabetes Investig"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000161","article-title":"Glycemic control and effects of canagliflozin on albuminuria and eGFR: post hoc analysis of the CREDENCE trial","volume":"18","author":"van der Hoek S","year":"2023","unstructured":"van der Hoek S, Jongs N, Oshima M, et al.. Glycemic control and effects of canagliflozin on albuminuria and eGFR: post hoc analysis of the CREDENCE trial. Clin J Am Soc Nephrol. 2023, 18:748-58. 10.2215\/CJN.0000000000000161","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.3405","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"5","author":"Xu L","year":"2017","unstructured":"Xu L, Li Y, Lang J, et al.. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ. 2017, 5:e3405. 10.7717\/peerj.3405","journal-title":"PeerJ"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1159\/000524889","article-title":"Initial eGFR changes with ertugliflozin and associations with clinical parameters: analyses from the VERTIS CV trial","volume":"53","author":"Cherney DZ","year":"2022","unstructured":"Cherney DZ, Cosentino F, Dagogo-Jack S, et al.. Initial eGFR changes with ertugliflozin and associations with clinical parameters: analyses from the VERTIS CV trial. Am J Nephrol. 2022, 53:516-25. 10.1159\/000524889","journal-title":"Am J Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4718","article-title":"How to read a funnel plot in a meta-analysis","volume":"351","author":"Sedgwick P","year":"2015","unstructured":"Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. BMJ. 2015, 351:h4718. 10.1136\/bmj.h4718","journal-title":"BMJ"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord RM","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006, 25:3443-57. 10.1002\/sim.2380","journal-title":"Stat Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20f13698","article-title":"Understanding the basics of meta-analysis and how to read a forest plot: as simple as it gets","volume":"81","author":"Andrade C","year":"2020","unstructured":"Andrade C. Understanding the basics of meta-analysis and how to read a forest plot: as simple as it gets. J Clin Psychiatry. 2020, 81:13698. 10.4088\/JCP.20f13698","journal-title":"J Clin Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-9. 10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/07435800.2025.2473896","article-title":"Management of diabetes in patients with chronic kidney disease","volume":"50","author":"Ambalavanan J","year":"2025","unstructured":"Ambalavanan J, Caramori ML. Management of diabetes in patients with chronic kidney disease. Endocr Res. 2025, 50:65-75. 10.1080\/07435800.2025.2473896","journal-title":"Endocr Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458132-sodium-glucose-cotransporter-2-inhibitors-in-diabetic-nephropathy-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:25:10Z","timestamp":1776255910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458132-sodium-glucose-cotransporter-2-inhibitors-in-diabetic-nephropathy-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.107083","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}